Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
13
11
2020
medline:
30
12
2020
entrez:
12
11
2020
Statut:
ppublish
Résumé
Malignant struma ovarii (MSO) is a rare malignant ovarian tumor, histologically identical to differentiated thyroid cancers. Given the rarity of this disease, there are no treatment guidelines, and the place of imaging for response assessment remains controversial. We report a metabolic response assessed by F-FDG PET/CT in a 71-year-old woman with radioiodine-refractory metastatic MSO treated by targeted therapies (first line with lenvatinib and second line with pazopanib). This case of exceptional response also highlights the usefulness of F-FDG PET/CT for therapeutic assessment of targeted drugs in such a rare clinical entity of malignant MSO.
Identifiants
pubmed: 33181745
doi: 10.1097/RLU.0000000000003374
pii: 00003072-202101000-00014
doi:
Substances chimiques
Iodine Radioisotopes
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-54Références
Siegel MR, Wolsky RJ, Alvarez EA, et al. Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literature. Arch Gynecol Obstet . 2019;300:1693–1707.
Seifert P, Gühne F, Theurer S, et al. Complete remission after single radioiodine therapy in malignant struma ovarii with bone and lymph node metastases. Clin Nucl Med . 2019;44:42–44.
Cherng SC, Wang YF, Fan YM, et al. Malignant struma ovarii with peritoneal implants and pelvic structures and liver metastases demonstrated by I-131 SPECT and low-dose CT. Clin Nucl Med . 2005;30:797–798.
Ranade R, Rachh S, Basu S. Late manifestation of struma peritonei and widespread functioning lesions in the setting of struma ovarii simulating highly differentiated follicular carcinoma. J Nucl Med Technol . 2015;43:231–233.
Tan A, Stewart CJR, Garrett KL, et al. Novel BRAF and KRAS mutations in papillary thyroid carcinoma arising in struma ovarii. Endocr Pathol . 2015;26:296–301.
Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J . 2019;8:227–245.
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol . 2010;11:962–972.